B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
AMRN
AmarinBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Partner-network demand growth, a completed cost-reduction initiative and $314.6 million of June 2026 cash could support value if they translate into sustained cash generation and Amarin-level revenue [#SEC-8K-2026-07-29].
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-27.
What can break
Failure to sustain lower operating expenses or positive cash flow would weaken the central thesis.
Momentum
13
Value
67
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $16.00 · Bear $8.00Analysis 2026-10-06; returns require an exact persisted reference.
Earnings
2026-10-27
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $12.50
Why
Momentum13 · Δ7d +5.7
Value67 · Δ7d -0.0
Sentiment59 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-27.
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Failure to sustain lower operating expenses or positive cash flow would weaken the central thesis.
- • Generic icosapent competitors provide product-market context, but their diversified businesses do not supply reliable company-level valuation comparables; analyst coverage and revisions are not established.
- • Q2 revenue declined 42% year over year and the company still reported an operating loss.
Catalyst clock
2026-10-27
2026 cash-flow and U.S. sales validation
Lead driver: Value · See fundamentals
Momentum
13
8% active weight
Current posture
7d trendImproving
Δ7d
+5.7
Δ21d
-
Value
67
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.6
Sentiment
59
45% active weight
Current posture
7d trendImproving
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 13.1 / Value 66.7 / Sentiment 58.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-06. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$255.38M
Beta
0.84
Shares Out
21.12M
P/E (TTM) · Derived
-6.5
P/S (TTM)
1.24
P/FCF (TTM) · Derived
16.24
Rev YoY
-42.6%
EPS YoY
-46.7%
Gross Margin
+40.4%
Op Margin
-12.9%
Net Debt
-$296.71M
Current Ratio
3.67
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data